XyloCor raises $67.5M Series B, updates pivotal gene therapy trial plans

XyloCor Therapeutics has closed a $67.5 million Series B round to fund mid-stage development of its cardiac gene therapy. Two years ago, the biotech said it hoped its next trials of the ...